Open-label, Extension Study of CDP870 in Patients With Rheumatoid Arthritis

Summary

This is a phase Ⅲ multicenter, open-label, follow-up study, to assess the safety and efficacy of certolizumab pegol (CZP) as additional medication to methotrexate (MTX), in patients with active rheumatoid arthritis (RA) who participated in Study (Protocol) # 101-KOA-0801i.

Timeline

Start

2010-03

Primary completion

2016-11

Completion

2016-11

Drugs

Indications